{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T02:09:42Z","timestamp":1783735782996,"version":"3.55.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Treatment with chimeric antigen receptor T (CAR-T) cells involves a large number of interdisciplinary stakeholders and is associated with complex processes ranging from patient-specific production to follow-up care. Due to the complexity, maximum process optimization is required in order to avoid efficiency losses. This study aimed at systematically determining the preconditions for a frictionless flow of the CAR-T process by surveying the stakeholders involved.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A Group Concept Mapping (GCM) analysis, a mixed-methods participatory research, was conducted. CAR-T experts from different professional backgrounds went through three steps: 1) Brainstorming relevant aspects (statements) for a frictionless process, 2) Sorting the collected statements based on their similarity, and 3) Rating the importance and feasibility of each statement. A cluster map reflecting the overarching topics was derived, and mean ratings per statement and cluster were calculated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 20 CAR-T experts participated. A total of 80 statements were collected, resulting in a map of the following 10 clusters (mean importance\/feasibility): Information for patients and physicians (4.16\/3.77), Supportive network (4.03\/3.53), Eligibility of patients (4.41\/3.63), Evidence, transparency and communication (4.01\/3.33), Paperwork (4.1\/2.52), Interface with pharmaceutical manufacturer (4.03\/2.85), Reimbursement (4.29\/2.31), Quality Management (4.17\/3.18), Infrastructure of CAR-T clinics (4.1\/2.93), and Patient-oriented processes (4.46\/3.32).<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>The 80 statements underlined the complex and manifold nature of the CAR-T treatment process. Our results reflect the first step in overcoming hurdles: identifying potential hurdles and required preconditions. Decision-makers and stakeholders can use the results to derive strategies and measures to further promote a frictionless process.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2024.1466803","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T05:10:19Z","timestamp":1727068219000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["How to optimize the CAR-T Cell therapy process? A group concept mapping analysis of preconditions for a frictionless process from a German multistakeholder perspective"],"prefix":"10.3389","volume":"14","author":[{"given":"Ann-Cathrine","family":"Siefen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melina Sophie","family":"Kurte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Jakobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Teichert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"von Tresckow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans Christian","family":"Reinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Holtick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Atta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Jehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Sala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Warnecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"H\u00e4nel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Scheid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Kron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,23]]},"reference":[{"key":"B1","volume-title":"Annex I - Summary of product characteristics (Abecma)","year":""},{"key":"B2","volume-title":"Annex I - Summary of product characteristics (Breyanzi)","year":""},{"key":"B3","volume-title":"Annex I - Summary of product characteristics (Carvykti)","year":""},{"key":"B4","volume-title":"Annex I - Summary of product characteristics (Kymriah)","year":""},{"key":"B5","volume-title":"Annex I - Summary of product characteristics (Tecartus)","year":""},{"key":"B6","volume-title":"Annex I - Summary of product characteristics (Yescarta)","year":""},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2024\/2239888","article-title":"Chimeric antigen receptor-T (CAR-T) cells as \u201cLiving drugs\u201d: A clinical pharmacist perspective","volume":"2024","author":"Murnane","year":"2024","journal-title":"J Clin Pharm Ther"},{"key":"B8","unstructured":"Advanced therapy medicinal products: Overview | European Medicines Agency"},{"key":"B9","unstructured":"Strengthening pathways for cell and gene therapies: current state and future scenarios\n          \n          \n          \n          2024"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023020854","article-title":"Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001","volume":"143","author":"Abramson","year":"2024","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018893","article-title":"5-year follow-up supports curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1)","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"B13","unstructured":"Yescarta"},{"key":"B14","unstructured":"Breyanzi"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"key":"B17","article-title":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Diagnostik, Therapie und Nachsorge f\u00fcr erwachsene Patient*innen mit einem diffusen gro\u00dfzelligen B-Zell-Lymphom und verwandten Entit\u00e4ten, Langversion 1.0, 2022, AWMF-Registernummer: 018\/038OL, Berlin, Germany","year":""},{"key":"B18","unstructured":"Diffuses gro\u00dfzelliges B-Zell-Lymphom"},{"key":"B19","unstructured":"Krebs in Deutschland f\u00fcr 2019\/2020\n          \n          \n          \n          2023"},{"key":"B20","unstructured":"Anlage XII \u2013 Beschl\u00fcsse \u00fcber die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach \u00a7 35a SGB V Axicabtagen-Ciloleucel\n          \n          \n          \n          2019"},{"key":"B21","unstructured":"Anlage XII \u2013 Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach \u00a7 35a SGB V Tisagenlecleucel (Neubewertung nach Fristablauf: Akute lymphatische B-ZellLeuk\u00e4mie)\n          \n          \n          \n          2020"},{"key":"B22","unstructured":"CAR-T-zellen status 2020"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1128295","article-title":"Comparative analysis of CAR T-cell therapy access for DLBCL patients: associated challenges and solutions in the four largest EU countries","volume":"10","author":"Canales Albendea","year":"2023","journal-title":"Front Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00108-021-01042-9","article-title":"[amp]]Ouml;konomie und Management bei der CAR-T-Zell-Therapie: Status quo und Ausblick","volume":"62","author":"Kron","year":"2021","journal-title":"Internist"},{"key":"B25","unstructured":"Richtlinie zu Anforderungen an die Qualit\u00e4t der Anwendung von Arzneimitteln f\u00fcr neuartige Therapien gem\u00e4\u00df \u00a7 136a Absatz 5 SGB V - CAR-T-Zellen bei B-Zell-Neoplasien"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s40290-022-00428-w","article-title":"Barriers to chimeric antigen receptor T-cell (CAR-T) therapies in clinical practice","volume":"36","author":"Gajra","year":"2022","journal-title":"Pharm Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.915342","article-title":"CAR T-cell therapies in Italy: patient access barriers and recommendations for health system solutions","volume":"13","author":"Jommi","year":"2022","journal-title":"Front Pharmacol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_279151","article-title":"Expanding access to chimeric antigen receptor T-cell therapies: challenges and opportunities","author":"Kansagra","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.04.003","article-title":"Overcoming barriers to referral for chimeric antigen receptor T cell therapy in patients with relapsed\/refractory diffuse large B cell lymphoma","volume":"29","author":"Hoffmann","year":"2023","journal-title":"Transplant Cell Ther."},{"key":"B30","unstructured":"CAR-T-Zelltherapie: Hoffnung und Herausforderung"},{"key":"B31","doi-asserted-by":"crossref","DOI":"10.4135\/9781412983730","volume-title":"Concept Mapping for Planning and Evaluation","author":"Kane","year":"2007"},{"key":"B32","year":""},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2019.10.4.12","article-title":"Educating multidisciplinary care teams, patients, and caregivers on CAR T-cell therapy","volume":"10","author":"Beaupierre","year":"2019","journal-title":"J Adv Pract Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2019.10.4.10","article-title":"Anti-CD19 CAR T-cell therapy for adult patients with refractory large B-cell lymphoma","volume":"10","author":"McDermott","year":"2019","journal-title":"J Adv Pract Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1186\/s12913-017-2741-y","article-title":"Determining requirements for patient-centred care: a participatory concept mapping study","volume":"17","author":"Ogden","year":"2017","journal-title":"BMC Health Serv Res"},{"key":"B36","doi-asserted-by":"crossref","first-page":"CD001431","DOI":"10.1002\/14651858.CD001431","article-title":"Decision aids for people facing health treatment or screening decisions","volume-title":"The Cochrane Database of Systematic Reviews","author":"O\u2019Connor","year":"2003"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1109\/ACCESS.2021.3118554","article-title":"Barriers to the diffusion of medical technologies within healthcare: A systematic review","volume":"9","author":"Warty","year":"2021","journal-title":"IEEE Access"},{"key":"B38","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/ejh.14095","article-title":"Cost-effectiveness analysis of transplant-ineligible relapsed or refractory diffuse large B-cell lymphoma treatment options\u2014Experience of the efficiency frontier approach","volume":"111","author":"Kurte","year":"2023","journal-title":"Eur J Haematol"},{"key":"B39","unstructured":"Entgelttarif f\u00fcr Krankenh\u00e4user im Anwendungsbereich des Krankenhausentgeltgesetzes (KHEntgG) und der Bundespflegesatzverordnung (BPflV) sowie Unterrichtung der Patientinnen und Patienten gem\u00e4\u00df \u00a7 8 KHEntgG\/\u00a7 8 BPflV - Charit\u00e9\n          \n          \n          \n          2024"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e736","DOI":"10.1097\/HS9.0000000000000736","article-title":"Budget impact analysis of CAR T-cell therapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma in Germany","volume":"6","author":"Skalt","year":"2022","journal-title":"HemaSphere"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1715536","DOI":"10.1080\/20016689.2020.1715536","article-title":"Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries","volume":"8","author":"J\u00f8rgensen","year":"2020","journal-title":"J Mark Access Health Policy"},{"key":"B42","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12962-022-00400-0","article-title":"Health economic analysis of third-line interventions in diffuse large B-cell lymphomas in Germany: applying the efficiency frontier","volume":"20","author":"Jakobs","year":"2022","journal-title":"Cost Eff Resour Alloc"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s12160-017-9876-2","article-title":"Cancer care coordination: a systematic review and meta-analysis of over 30 years of empirical studies","volume":"51","author":"Gorin","year":"2017","journal-title":"Ann Behav Med"},{"key":"B44","article-title":"Cancer care coordinators: what are they and what will they cost","volume":"126","author":"Collinson","year":"2013","journal-title":"N Z Med J."},{"key":"B45","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s12912-021-00684-2","article-title":"A literature-based study of patient-centered care and communication in nurse-patient interactions: barriers, facilitators, and the way forward","volume":"20","author":"Kwame","year":"2021","journal-title":"BMC Nurs"},{"key":"B46","doi-asserted-by":"publisher","first-page":"5746","DOI":"10.3390\/cancers15245746","article-title":"The impact of outpatient versus inpatient administration of CAR-T therapies on clinical, economic, and humanistic outcomes in patients with hematological cancer: A systematic literature review","volume":"15","author":"Hansen","year":"2023","journal-title":"Cancers"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.636068","article-title":"Chimeric antigen receptor T cell therapy management and safety: A practical tool from a multidisciplinary team perspective","volume":"11","author":"Marzal-Alfaro","year":"2021","journal-title":"Front Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1136\/bmjqs-2013-001862","article-title":"Systematic review of the application of the plan\u2013do\u2013study\u2013act method to improve quality in healthcare","volume":"23","author":"Taylor","year":"2014","journal-title":"BMJ Qual Saf"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1466803\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T05:10:36Z","timestamp":1727068236000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1466803\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,23]]},"references-count":48,"alternative-id":["10.3389\/fonc.2024.1466803"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1466803","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,23]]},"article-number":"1466803"}}